# US 10,765,692 B2 · Maribavir isomers, compositions, methods of making and methods of using

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,765,692 B2
- Document ID: US10765692B2
- Status: Granted
- Kind: B2
- Application number: 16/663,743
- Filed: 2019-10-25
- Published: 2020-02-20
- Granted: 2020-09-08
- Earliest claimed: 2010-10-28
- Assignees: Shire ViroPharma Incorporated
- Applicants: Shire ViroPharma Incorporated
- Inventors: John D. Peabody, III
- Web page: https://patentgrep.com/patent/US10765692B2

## CPC

- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/22: for herpes viruses
- G01N 33/94: involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
- G09B 19/00: Teaching not covered by other main groups of this subclass (teaching or practice apparatus for gun-aiming or gun-laying F41G3/26)
- G01N 2430/00: Assays, e.g. immunoassays or enzyme assays, involving synthetic organic compounds as analytes
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G09B: EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS (devices for psychotechnics or for testing reaction times A61B5/16; games, sports, amusements A63; projectors, projector screens G03B)

## Abstract

The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

## Claims

### Claim 1

A composition comprising maribavir and at least one of an antacid which is effective for neutralizing acid that catalyzes isomerization of maribavir, (ii) an antibiotic having activity against a microorganism that mediates isomerization of maribavir, or (iii) an antagonist that inhibits metabolism that induces isomerization of maribavir, said isomerization producing a decrease in the therapeutic efficacy of maribavir.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition comprises maribavir and an antacid which is effective for neutralizing acid that catalyzes isomerization of maribavir.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said composition comprises maribavir and an antibiotic having activity against a microorganism that mediates isomerization of maribavir.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said composition comprises maribavir and an antagonist that inhibits metabolism that induces isomerization of maribavir, said isomerization producing a decrease in the therapeutic efficacy of maribavir.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said composition comprises at least 100 mg of maribavir.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said composition comprises up to 3200 mg of maribavir.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said composition is an immediate release formulation, a delayed release formulation, a controlled release formulation or an intravenous formulation.

### Claim 8 (depends on 1)

The composition of claim 1, wherein said composition is formulated for oral administration.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said composition is formulated for intravenous administration.